Portfolio company
ABIONYX Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops recombinant HDL-based biotherapies for patients with sepsis, renal diseases, and ophthalmological conditions.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Cerenis Therapeutics Holding SA
This biopharmaceutical company develops high-density lipoprotein therapies to treat patients with cardiovascular and metabolic diseases, as well as renal and oncology conditions.
Nionyx Bio
The company develops adeno-associated virus gene therapies for patients with genetic kidney diseases.
Abliva
This biopharmaceutical company develops novel medicines for patients suffering from rare and severe primary mitochondrial diseases.
AMYL THERAPEUTICS
The company develops pan-amyloid immunotherapies to treat patients with neurodegenerative and rare diseases caused by toxic protein aggregates.
Ablynx NV
This company develops nanobody-based therapeutic proteins to treat inflammation, haematology, oncology and pulmonary diseases for pharmaceutical partners and patients.
AB2 Bio
This company develops Tadekinig alfa, a recombinant protein treatment for patients suffering from severe IL-18 driven systemic autoinflammatory and hyperinflammatory diseases.
Aviceda
This biotechnology company develops nanoparticle glyco-therapeutics for patients with immune-mediated diseases, primarily targeting macular degeneration and other ophthalmic, neurological and inflammatory conditions.
Iveric Bio
This biopharmaceutical company develops therapeutic treatments for retinal diseases and provides these medicines to patients with age-related macular degeneration and inherited conditions.